.svg)
Want an email alert every time a Finch Trade goes live? Sign up in your profile.
As communicated previously, I purchased this position only to play a likely earnings pop and expected to sell it immediately. My exit is not a judgement on the near- or long-term prospects of the business, which is objectively well-positioned to continue growing and earning a durably higher valuation.
Blueprint Medicines reported year-over-year Ayvakit revenue growth of 61%, increased the midpoint of full-year 2025 revenue guidance from $695 million to $710 million, and generated cash when its equity stake in IDRx was acquired by GlaxoSmithKline. The business exited March 2025 with $900 million in cash and is firmly in control of its financial destiny, as it can self-fund the commercial ramp of Ayvakit and its emerging pipeline.
This is the first time a Finch Trades position has been closed.
The Trade
I sold 113.37 shares of Blueprint Medicines at $98.73 per share on May 1, 2025.
This position was closed, resulting in a one-day gain of 11.9% and $1,193. The S&P 500 gained 3.1% while the position was active, resulting in a net outperformance of 8.9% compared to passive investing. This will help bolster the overall performance of Finch Trades and help to offset more volatile, long-term positions in precommercial drug developers.
Margin of Safety & Allocation
Blueprint Medicines is considered a Growth (Quality) position. Coverage will be initiated soon.
Further Reading
- April 2025 Member Digest previewing Q1 2025 earnings from the coverage ecosystem
.svg){kind=icon}
.avif)
.png)
-cropped.svg)
.svg){kind=small}